NCT03816696View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 23, 2019

Primary Completion Date

March 30, 2019

Study Completion Date

April 10, 2019

Conditions
HIV Infections
Interventions
DRUG

GSK3640254

GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.

DRUG

DTG

DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY